Abstract
The scope of flow cytometry is rapidly expanding in the diagnosis of various cancers, and it is being used routinely as an aid in classifying leukemias and lymphomas. There are several applications of flow cytometry to enumerate tumorigenic anomalies in patients. The unusual distribution of cells in various locations, their DNA content, cell proliferation rate, dysregulated expression of several surface receptors, and expression of tumor antigens are some examples that can be characterized by using different flow cytometry-based techniques. For instance, the differential diagnosis between chronic lymphocytic leukemia (CLL) and various other mature B-cell neoplasms can be made by immunophenotyping in combination with absolute counting of numerous cellular subsets or by enumerating their percent distributions. Flow cytometry has several advantages over conventional techniques which include the ability to acquire a multiparametric data in a relatively shorter time and facilitate the comparative analysis of specific cellular subsets in an efficient manner.
In addition to diagnosis, there are several other applications of flow cytometry in the management of various cancers which include treatment monitoring or even selecting a personalized precision-based immunotherapy in synch with advanced genetic tests to increase the chances of favorable prognosis and complete remission. The detection of chimeric antigen receptors (CARs) on various engineered effector cells can also be determined along with their specificity in engaging the targets. Furthermore, the assessment of numerous immunological parameters, their effector functions and potencies including the proliferation dynamics, cytokine secretion profiles, and activation efficiencies can also be measured before starting immunotherapies in patients.
This chapter is a brief overview of flow cytometry applications in the diagnosis and treatment strategies of various cancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cossarizza A, Chang HD, Radbruch A et al (2019) Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol 49(10):1457–1973. https://doi.org/10.1002/eji.201970107
Greig B, Oldaker T, Warzynski M et al (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: recommendations for training and education to perform clinical flow cytometry. Cytometry B Clin Cytom 72(Suppl 1):S23–S33. https://doi.org/10.1002/cyto.b.20364
Gaidano V, Tenace V, Santoro N et al (2020) A clinically applicable approach to the classification of B-cell non-Hodgkin lymphomas with flow cytometry and machine learning. Cancers (Basel) 12(6). https://doi.org/10.3390/cancers12061684
Grewal RK, Chetty M, Abayomi EA et al (2019) Use of flow cytometry in the phenotypic diagnosis of Hodgkin’s lymphoma. Cytometry B Clin Cytom 96(2):116–127. https://doi.org/10.1002/cyto.b.21724
Beresford MJ, Wilson GD, Makris A (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8(6):216. https://doi.org/10.1186/bcr1618
Kim KH, Sederstrom JM (2015) Assaying cell cycle status using flow cytometry. Curr Protoc Mol Biol 111:28.26.1–28.26.11. https://doi.org/10.1002/0471142727.mb2806s111
Bologna-Molina R, Mosqueda-Taylor A, Molina-Frechero N et al (2013) Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Med Oral Patol Oral Cir Bucal 18(2):e174–e179. https://doi.org/10.4317/medoral.18573
Cho Mar K, Eimoto T, Nagaya S et al (2006) Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 48(7):801–807. https://doi.org/10.1111/j.1365-2559.2006.02430.x
Stingl J, Emerman JT, Eaves CJ (2005) Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity. Methods Mol Biol 290:249–263. https://doi.org/10.1385/1-59259-838-2:249
Garaud S, Gu-Trantien C, Lodewyckx JN et al (2014) A simple and rapid protocol to non-enzymatically dissociate fresh human tissues for the analysis of infiltrating lymphocytes. J Vis Exp 94:doi:10.3791/52392
Tario JD Jr, Conway AN, Muirhead KA et al (2018) Monitoring cell proliferation by dye dilution: considerations for probe selection. Methods Mol Biol 1678:249–299. https://doi.org/10.1007/978-1-4939-7346-0_12
Mishra HK, Dixon KJ, Pore N et al (2021) Activation of ADAM17 by IL-15 limits human NK cell proliferation. Front Immunol 12:711621. https://doi.org/10.3389/fimmu.2021.711621
Gafter-Gvili A, Polliack A (2016) Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma 57(3):512–519. https://doi.org/10.3109/10428194.2015.1110748
Skarbnik AP, Faderl S (2017) The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol 8(3):99–105. https://doi.org/10.1177/2040620716681749
Xenia Elena B, Nicoleta Gales L, Florina Zgura A et al (2021) Assessment of immune status in dynamics for patients with cancer undergoing immunotherapy. J Oncol 2021:6698969. https://doi.org/10.1155/2021/6698969
Chan KS, Kaur A (2007) Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. J Immunol Methods 325(1–2):20–34. https://doi.org/10.1016/j.jim.2007.05.011
Mishra HK, Pore N, Michelotti EF et al (2018) Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNgamma production by human NK cells in the presence of antibody-bound tumor cells. Cancer Immunol Immunother 67(9):1407–1416. https://doi.org/10.1007/s00262-018-2193-1
Zheng Z, Chinnasamy N, Morgan RA (2012) Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med 10:29. https://doi.org/10.1186/1479-5876-10-29
Jena B, Maiti S, Huls H et al (2013) Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8(3):e57838. https://doi.org/10.1371/journal.pone.0057838
Hu Y, Huang J (2020) The chimeric antigen receptor detection toolkit. Front Immunol 11:1770. https://doi.org/10.3389/fimmu.2020.01770
Zhang H, Zhao P, Huang H (2020) Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol 9(1):34. https://doi.org/10.1186/s40164-020-00190-2
Arcangeli S, Falcone L, Camisa B et al (2020) Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. Front Immunol 11:1217. https://doi.org/10.3389/fimmu.2020.01217
Wang W, Erbe AK, Hank JA et al (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368. https://doi.org/10.3389/fimmu.2015.00368
Doan M, Vorobjev I, Rees P et al (2018) Diagnostic potential of imaging flow cytometry. Trends Biotechnol 36(7):649–652. https://doi.org/10.1016/j.tibtech.2017.12.008
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Mishra, H.K. (2023). Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to Treatments. In: Kalyuzhny, A.E. (eds) Signal Transduction Immunohistochemistry. Methods in Molecular Biology, vol 2593. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2811-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2811-9_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2810-2
Online ISBN: 978-1-0716-2811-9
eBook Packages: Springer Protocols